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Orphan Drugs, only the Eculizumabe for the treatment of PNH has no approved 
registration by the National Health Surveillance Agency (ANVISA). ConClusions: 
Considering its high cost, high judicial demand and limited availability of scientific 
evidence, orphan drugs represent a challenge for researchers and decision makers. 
Clinical benefit, disease severity, availability of therapeutic alternatives, ethical, 
political and social aspects should be considered. It is necessary to start a multi-
disciplinary reflection on the development of HTA models and policies regarding 
rare diseases and innovative treatments in the SUS, as well as fostering the primary 
researches in this field.
PSY106
To WhaT ExTEnT Do DiSEaSE anD TrEaTmEnT CharaCTEriSTiCS 
influEnCE hTa-BaSED rECommEnDaTionS for a SamPlE of orPhan 
DrugS in ThrEE CounTriES, anD CoulD ThESE inDiCaTE WhEThEr orPhan 
DrugS havE a “SPECial STaTuS”?
Nicod E.
London School of Economics and Political Science, London, UK
Routine HTA methods may not adequately capture all the important considerations 
of a treatment’s value and the impact of the condition on the patient given that 
evidence is often incomplete. This study aims to explore the influence of broader con-
siderations of scientific and social value judgments on reimbursement decisions for 
a sample of orphan drugs.objeCtives: To identify and compare the extent to which 
these broader considerations not captured by the incremental cost-effectiveness ratio 
(ICER) influenced HTA decision-making process in three countries; and, on this basis, 
explore whether orphan drugs have a “special status”. Methods: Countries included 
were England, Scotland and Sweden. Ten drug-indication pairs with EMA orphan des-
ignation and all appraised by NICE were selected. Publicly available HTA reports were 
coded using thematic analysis to systematically identify and compare these broader 
considerations across countries using an existing analytical framework. Results: 
108 different other considerations were identified and grouped into 15 clusters based 
on the information provided. The most common related to the nature of the disease, 
and considerations based on rarity or unmet need. 52% were one of the main reasons 
for the decision, and in some cases, were also a pivotal factor in accepting high and 
uncertain ICERs. Categorising these as social or scientific value judgments was done 
to identify areas where further elicitation of societal preferences, and where more 
consistency and transparency in their use are needed, respectively. Each of these was 
then compared to determine whether they pertained specifically to orphan drug or 
rare disease characteristics. ConClusions: Considerable variation was seen in the 
application of these broader considerations. Identifying these is a way forward to 
highlight areas where more research, or consistency and transparency are needed. 
Some of these other considerations may also favour orphan drugs, furthering the 
debate around whether orphan drugs deserve special status.
PSY107
WhY arE ThErE DiffErEnCES in hTa rECommEnDaTionS aCroSS 
CounTriES? a SYSTEmaTiC ComPariSon of hTa DECiSion ProCESSES for a 
SamPlE of orPhan DrugS in four CounTriES
Nicod E.
London School of Economics and Political Science, London, UK
HTA reimbursement recommendations often result in different outcomes across 
countries despite the same evidence being appraised for a same technology. There 
is a need to understand the reasons for these differences. objeCtives: To system-
atically compare HTA processes for a sample of orphan drugs across four countries 
(England, Scotland, Sweden, France): to identify the use and interpretation of the evi-
dence appraised, and highlight differences across countries. Methods: Ten orphan 
drug-indication pairs were selected and systematically compared using a previously 
validated framework. An exploratory sequential mixed methods design divided the 
research into two stages: (1) qualitative in-depth analysis of the decision-making 
processes; and (2) quantitative identification of agency-specific risk preferences 
and agreement levels across countries. Results: Differences at each step of the 
decision-making process were identified. The same pivotal trials were appraised 
but with varying levels of detail in reporting the clinical outcomes, explaining some 
of the reasons for differing HTA recommendations. Agency-specific risk prefer-
ences were identified through correspondence analysis as drivers of these deci-
sions, further explaining some of these differences. Poor to moderate agreement in 
the interpretation of the evidence was measured using Cohen’s kappa scores. This 
reflected situations where the countries interpreted the same evidence differently 
and situations where differences in the handling of the same uncertainties were 
seen, including differences in the extent to which stakeholder input influenced a 
decision. ConClusions: This research systematically compared HTA processes 
in different countries, facilitating the understanding of these complex processes 
including how different HTA bodies conduct value assessments. It enabled to raise 
awareness around the reasons for differences across countries, and highlight 
areas for potential methodological improvements in HTA. Further application of 
this framework to other disease areas and countries is a way forward to improv-
ing the drivers of coverage decisions while better understanding the settings and 
limitations of HTA.
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ToP 20 orPhan DrugS availaBiliTY, PriCing anD rEimBurSEmEnT in 
Slovakia: 2005-2012 rEviEW
Babela R.1, Uraz V.2, Babelova O.2, Slezakova Z.1
1St. Elizabeth University, BRATISLAVA, Slovak Republic, 2St. Elizabeth University, Bratislava, 
Slovak Republic
objeCtives: Orphan drugs are highly priced and top 20 orphan drugs create almost 
2,5% of total drug expenditure in Slovakia. We conducted 8 years review of govern-
ment and literature sources to provide insight into pricing, reimbursement and 
availability situation surrounding top 20 orphan drugs in Slovakia from the health 
care payer perspective. Methods: We provide analysis of official prices, reim-
15% to 100%. In Italy only 9 molecules are reimbursed in retail pharmacy and other 
10 are not reimbursed at all. In 63% cases ex-factory prices in Italy are higher than 
in France. The average price difference in price is 12 % with 50% of products sharing 
almost same price (less than 5% difference). No information is available in France on 
managed entry agreement, while it is publicly available in Italy. This prevents fair 
price comparison. ConClusions: OD are more available in Italy, but reimburse-
ment is poorer than in France. Prices are slightly higher in Italy but France displays 
multiple confidential rebates making it impossible to compare net prices. In Italy 
the actual accessibility depends a lot on regional level unlike France.
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hEalTh TEChnologY aSSESSmEnT, PriCE anD rEimBurSEmEnT rEviEW 
for orPhan DrugS in iTalY
Tavella F.1, Korchagina D.2, Rodrigues J.2, Rémuzat C.2
1Creativ-Ceutical, London, UK, 2Creativ-Ceutical, Paris, France
objeCtives: In Italy drug Health Technology Assessment (HTA) is conducted by the 
Scientific Technical Commission of Italian Medicines Agency (AIFA) with further 
negotiation between the manufacturers and the AIFA’s Pricing & Reimbursement 
Committee on price and reimbursement. After the decision is taken it is published 
in the official journal (Gazetta officale), the assessed drug is formally available 
for Italian patients next day. There does not exist a specific procedure for orphan 
drugs (OD), they are evaluated under the same conditions as drugs for common 
diseases. Pharmaco-economic studies are recommended for innovative drugs. The 
objective of the study is to review HTA decisions, prices and reimbursement of OD 
in Italy. Methods: All OD assessed in Italy since 2000 were identified. Prices, reim-
bursement rates and decision details were extracted for each drug using Farmadati 
Italia database. Results: Among 74 OD approved in Europe 66 molecules are offi-
cially available in Italy. It took 5-10 months from granting market authorization to 
final decision on pricing and reimbursement and publication in ‘Gazetta officale’. 
The mean time was about 17 months shorter than for common drugs. Only 9 of 
available molecules are fully reimbursed in Italy, reimbursement of 30 drugs is 
restricted to hospital use, 10 are not reimbursed and 5 are in a special class waiting 
a decision on reimbursement rate. For other drugs information is not available. Post-
marketing surveillance studies were requested for a half of indications, AIFA regis-
tries were reported in 25% of cases. Annual treatment ex-factory price of OD varies 
from € 2 500 to almost € 1 000 000. ConClusions: Almost 90% of approved OD are 
available in Italy. However, the actual situation often differs a lot from the official 
data as some drugs are unavailable from retail or hospital pharmacies. In addition, 
regional authorities contribute to inequity in access especially for “expensive drugs”.
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hEalTh TEChnologY aSSESSmEnT, PriCE anD rEimBurSEmEnT rEviEW 
for orPhan DrugS in franCE
Korchagina D.1, Rémuzat C.1, Rodrigues J.1, Kornfeld A.2, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ Ceutical, Paris, France, 3University of Marseille, 
Marseille, France
objeCtives: In France Orphan Drugs (OD) undergo the same Health Technology 
Assessment (HTA) procedure as other drugs. The evaluation is performed by the 
Transparency Committee (TC). Two scores are assigned and further used for pric-
ing & reimbursement decision: drug’s medical benefit (SMR) and improvement in 
medical benefit (ASMR). OD can be eligible to an accelerated procedure established 
for innovative products. The study aim is to analyse HTA decisions, prices and reim-
bursement of OD in France. Methods: Exhaustive prices, reimbursement and HTA 
opinions were extracted using Transparency Committee Website, AMELI’s national 
health insurance and Thériaque databases. Results: Among 74 OD approved 
in Europe, 21 drugs are not available in France. 6 were recently assessed by TC 
but are not yet reimbursed, 14 were not assessed and one got a negative opinion. 
Reimbursement process took between 2 and 5 months after TC opinion. 88% of 
drugs were considered as bringing a substantial medical benefit. At the same time, 
more than a half of medicines were graded as providing a major (9%), significant 
(27%) or moderate (20%) improvement in actual benefit leading to opportunity for 
premium prices, 30% were rated minor improvement, and about 14% no improve-
ment according to TC opinion. Annual treatment prices of OD varie from € 1,500 to 
almost € 1,000,000. ConClusions: About a third of approved ODs are not available 
in France. Most of them were authorized recently and are might become available 
after the HTA and pricing process. In comparison to non OD, the ASMR scoring is 
outstanding. Lack of alternative treatment and severity of the condition appear to 
be the drivers of high SMR-ASMR score.
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hTa STuDiES on orPhan DrugS BY rEBraTSxmEmBErS
Souza K.M.1, Gonçalves L.2
1Brazilian Ministry of Health, Brasília, Brazil, 2Brazilian Ministry of Health, Brasília-DF, Brazil
objeCtives: In Brazil, the studies produced by members of the Brazilian Network 
for Health Technology Assessment (REBRATS) have contributed in a significant way 
in the process of management and incorporation of technologies in the Brazilian 
Public Health system (SUS). However, there is still a lack of a Pharmaceutical 
Assistance and HTA Policy for rare diseases and the evidence for orphan drugs are 
limited and lower. The coverage for these drugs, is frequently done through judicial 
orders, political and social pressure, with no support of evidence-based medicine. 
The objectives is to evaluate the production of HTA studies for orphan drugs made 
by REBRATS members. Methods: Query to the REBRATS database and the internal 
production of the HTA coordination, prioritizing 6 major diseases: Gaucher dis-
ease, Fabry disease, Mucopolysaccharidosis Type I (MPS I); Mucopolysaccharidosis 
Type II (MPS II); Mucopolysaccharidosis Type VI (MPS VI); Paroxysmal Nocturnal 
Haemoglobinuria (PNH). Results: Five HTA studies were found, which are: a 
Rapid Response for Gaucher disease; a study on Health Technology Management 
for Fabry disease; an Economic Evaluation for MPS I, II and VI; a Systematic Review 
for Mucopolysaccharidosis Type II; and one Rapid Review for PNH. For the evaluated 
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and events attributed to OIC including the negative impact on job-related activi-
ties. Methods: A prospective longitudinal study conducted in the United States 
(US), Canada (CN), UK (UK), and Germany (GE) of patients with OIC who have been 
on opioid therapy for at least four weeks was conducted. OIC related medical history 
and health care resource use was collected from participants self report. The num-
ber of hours missed from work and the extent to which the work productivity and 
regular daily activities were affected was collected using the WPAI-SHP. Results: 
A total of 489 eligible participants (US: 238; CN: 38;, GE: 115; UK: 98). Back pain 
(77%) and joint pain (52%) were the most common pain diagnosis with an average 
duration of chronic pain and opioid medication use of 10 and 6 years respectively. 
27% of participants were currently employed. 18% of participants used at least 
one prescription laxative; 70% reported using at least one over-the-counter (OTC) 
laxative with the most common being stimulant laxatives (20%), osmotic laxatives 
(15%) and stool softeners (7%). 63% of participants reported discussing OIC with a 
health care provider, 3.0% reported a visit to the emergency room and 2.0% reported 
being admitted to a hospital because of their OIC during a 6-month time period. 
9% of employed participants reported missing an average of 4.6 hours per week 
because of problems associated with constipation and 32% reported impairment 
while working due to constipation. ConClusions: The cumulative impact of OTC 
use, physician office visits and the negative impact on work-related activities for 
OIC may be substantial.
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hEalTh CarE uTiliSaTion anD SElECTED ExPEnDiTurES aSSoCiaTED WiTh 
nEuroBlaSToma in EnglanD
George S.1, Buckle J.2
1Milliman, Tampa, FL, USA, 2Milliman, London, UK
objeCtives: Neuroblastoma (NB) is a rare cancer of childhood, with nearly 90% of 
cases diagnosed by age 5 (ACS 2013). Our objective was to report the utilisation and 
cost of hospital services related to patients who have a diagnosis of NB and High 
Risk NB (HRNB) reported in an England dataset from a Clinical Commissioning 
Group (CCG) perspective. Methods: We used an England dataset covering hospi-
tal events (April 2010 - September 2013). Patients were included if they were under 
age 18 and had a hospital event with a primary or secondary diagnosis coded as 
International Classification of Disease 10thEdition (ICD10) C749. Newly diagnosed 
patients were identified if they had no hospital events in the first 4 months of 
the study period. From this newly diagnosed cohort we identified a HRNB cohort 
(bone marrow transplant) that included patients who had a high risk procedure 
that did not occur in the last 12 months of the study period. Cost and utilisation is 
reported from hospital admissions, emergency department visits, and outpatient 
attendances. Results: We observed 336 patients as newly diagnosed and an addi-
tional 33 patients were identified as HRNB. Newly diagnosed population inpatient 
admits were 12 per patient, compared with 22 per patient for the HRNB population. 
Total costs associated with the 336 newly diagnosed patients were £24.3m. Total 
costs associated with the 33 HRNB patients were £4.3m. Costs per HRNB patient 
(£130,303) were almost double the costs per newly diagnosed patient (£72,321). 
The average length of stay was 6 days for both sets of patients. ConClusions: 
To our knowledge this is the first retrospective analysis of NB cost and utilisation 
using encounter data from England. While it does not capture the entire costs to 
the England health care system, it indicates the level of resource intensity and 
cost at the CCG level.
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DaTaBaSE analYSiS on PaTiEnTS uSing immunoBiologiCal DrugS in a 
Brazilian PrivaTE hEalTh CarE Plan: a rEal WorlD DaTa analYSiS
Reis H.P.L.C.1, Viana A.D.J.R.1, Magalhães D.D.P.1, Alcantara A.C.D.C.1, Sartori D.P.1, Vieira J.B.1, 
Ferreira J.2, Rodrigues E.X.1, Filho N.G.1
1Unimed Fortaleza, Fortaleza, Brazil, 2UFC, Fortaleza, Brazil
objeCtives: Patients’ profile undergoing intravenous immunobiological treatment 
is very limited. This study aimed to describe this information from the perspective of 
a Brazilian health plan, located in Fortaleza. Methods: This was a cross sectional 
study with data obtained from the HMO database as presented by Reis H et al at 
ISPOR 18th Annual Meeting. Eligible criteria for data analysis were patients being 
treated for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis 
(PsA) or Crohn’s disease (CD) who have received at least one dose of immunobiologi-
cal drug between March/2012 and October/2013. Data was stratified by indication 
(RA, AS, PsA and CD), patient weight and treatment profile (naïve versus non-naïve 
patients). Results: A total of 118 patients had been analyzed, with an average 
age of 51 years, and 66.9% (n = 79) of them being women. RA (n = 53,44,9%) and AS 
(n = 49,41,5%) were the most prevalent diseases being treated, followed by PsA 
(n = 13,11%) and CD (n = 3,2, 5%). The average weight of patients varied according 
to the disease being treated: 67 kg for RA and CD, and 70 kg for AS and PsA. It was 
observed that 65.5% patients were naïve to immunobiological drug, of which 73% 
initiated treatment with an anti-TNFa, being infliximab the most commonly pre-
scribed one (85.2%). As for patients who had already been previously treated, goli-
mumab and abatacept were the most commonly prescribed drugs (23%), whereas 
48.7% out of total were receiving the third immunobiogical drug and 35.9% were 
receiving the second one. ConClusions: The knowledge of patients profile and 
treatment information is the basis for any planning strategy in an HMO. Associated 
with costs, this data is crucial in supporting HMO board decisions on best treatment 
alternatives and so optimize the provided care.
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mulTi-CriTEria DECiSion analYSiS for rEimBurSing orPhan DrugS: a 
DuTCh DEmonSTraTion STuDY uSing ThE analYTiC hiErarChY ProCESS 
mEThoD
Trip A.M.1, Tsiachristas A.1, Koenders J.M.2, Kanters T.A.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Novartis Pharma B.V., Arnhem, 
The Netherlands
bursement status and availability of top 20 orphan drugs in Slovakia from 2005 
till 2012. Data were obtained from government sources. Results: We considered 
orphan drugs list (Cote and Keating, 2012) that exceeded 1 billion $ sales in 2008 
(globally) and compared molecules’ availability in Slovakia. Same molecules are 
among best selling 20 orphan drugs in Slovakia, with highest sale of 95 million EUR 
(Bevacizumab, 2005-2012) compared to lowest sale of 19 million EUR (Tacrolimus, 
2005-2012). It took from 1 (Imatinib) to 19 years (Glatiramer acetate) to be launched 
in Slovakia after orphan designation. Top 20 orphan drugs had average DOT 472 
EUR compared to total pharma market DOT average 0,43 EUR. From selected orphan 
drugs 60% had full (100%) reimbursement status and 40% were fully covered by 
hospital budgets. Only 4 of them were launched in Slovakia since 2005 (included), 16 
of them were launched from 1990 till 2004. Prices ranged from 330 EUR to 5800 EUR 
(ex-factory, one package, 2012). ConClusions: There are highly valuable incentives 
for industry to invest in to development of orphan drugs in EU. Current context of 
economic constraints in EU however justifies the need to pay close attention to the 
rationale of maintaining such incentives in the context of potential return on invest-
ments of companies offering high priced drugs. Top 20 orphan drugs in Slovakia 
have prices high above average and also full reimbursement status. We expect more 
restrictive drug policy measures in this field.
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EffECT of ExCluDing non-PaTiEnT BEnEfiTS aS an ElEmEnT on aCmg 
nEWBorn SCrEEning (nBS) rECommEnDaTionS
Mahida S., Algarni M., Rittenhouse B.
MCPHS University, Boston, MA, USA
objeCtives: In 2006 the American College of Medical Genetics (ACMG) developed 
a stakeholder survey to make recommendations for 84 rare conditions to be con-
sidered for mandatory newborn screening (NBS). Scores of 19 different surveyed 
attributes for each condition were totaled. These scores determined an entry point 
to an algorithm (EPA) that determined final recommendations (Core conditions, 
Secondary Targets or Not Recommended). Among these attributes was a contro-
versial one - non-patient benefits (NPB). Such attributes have historically not been 
considered in mandatory screening recommendations. This analysis examines 
how the exclusion of this attribute would affect recommendations. Methods: 
The ACMG report provided scores for individual attribute survey responses. We 
deleted the attribute score for NPB (0 to 100 points) and rescored the totals for 
each condition. We then assessed whether score changes were sufficient to alter 
the EPA and whether a different EPA would result in changes to the recommenda-
tions. Results: Six conditions had missing data. Of the 78 remaining, there were 
15 conditions (19%) whose initial total scores were capable of changing by enough 
in this exercise (maximum 100 point reduction) to change the EPA. Of those, 10 (67%) 
did change EPA and, of those, 3 (30%) changed final category (in all cases from Core 
to ST). Of the initial 29 recommended Core conditions, there would be a 10 percent 
reduction to 26 and an increase in Secondary Targets from 25 to 28. ConClusions: 
Including screening benefits to non-patients (family or society) is controversial 
and has not been standard in the past. We have shown that in the ACMG recom-
mendations, had no changes been made to the algorithm consequent to dropping 
non-patient benefits from consideration, 3 conditions would have changed from a 
Core recommendation for screening to only a Secondary Target.
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aCCESS To orPhan DrugS in grEECE During EConomiC CriSiS
Tsiantou V.1, Mylona K.1, Karampli E.1, Boubouchairopoulou N.1, Kyriopoulos I.I.1, 
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1National School of Public Health, Athens, Greece, 2Institute of Pharmaceutical Research and 
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objeCtives: Orphan Drugs (ODs) are medicinal products intended for diagnosis, 
prevention or treatment of rare diseases. Access to ODs is crucial for patients’ health 
and quality of life. The aim of this study was to identify current problems and future 
challenges of patients’ access to ODs in Greece. Methods: A qualitative study took 
place between December 2013 and January 2014. Data were retrieved through semi-
structured interviews with six representatives of key stakeholders in Greece and 
policy documents identified through web searches using keywords “orphan drugs” 
and “rare diseases” in Greek. Web-based documents and transcribed interviews were 
content analyzed. Results: Delays in pricing and reimbursement of ODs in the 
Greek pharmaceutical market, budget cuts in hospitals and absence of patient reg-
istries constitute according to the analysis the greatest barriers in patients’ access 
to ODs. There are two main channels through which the patient can have access 
to an OD and it depends whether it is licensed in Greece or not. In the first case 
the patient can take the drug through the hospital or the pharmacy of EOPYY if it 
is not available at the hospital pharmacy and in the second case through a public 
sector organization (IFET). All cases are characterized by extensive bureaucracy and 
involvement of up to three organizations in order to receive the approval, a proce-
dure creating delays in patients’ access and risking their health. Also, the absence of 
a well-described procedure and lack of cooperation between the organizations and 
committees create further delays. ConClusions: Ensuring patients’ access to ODs 
in Greece is challenging especially during the economic crisis. Financial constraints 
and continuous legislative changes in the health system and the pharmaceutical 
market constitute important barriers to patients’ access. There is a need to describe, 
organize and communicate the pathway of patients’ access to ODs.
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SElf rEPorTED hEalTh CarE rESourCE uSE anD inDirECT EConomiC 
BurDEn of oPioiD inDuCED ConSTiPaTion (oiC)
Alemayehu B.1, Coyne K.S.2, King F.3
1AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 2Evidera, Bethesda, MD, USA, 
3AstraZeneca, Gaithersberg, MD, USA
objeCtives: To describe the health care resource utilization associated with the 
diagnosis, treatment, and general management of opioid-induced constipation (OIC) 
